DaZhu Rhodiola Rosea Capsule for Coronary Artery Disease With Angina Pectoris
NCT ID: NCT03633890
Last Updated: 2018-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
102 participants
INTERVENTIONAL
2018-08-31
2019-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rhodiola Rosea for Coronary Microvascular Disease
NCT04218916
Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina.
NCT03171597
Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index
NCT01502943
Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina.
NCT03179618
Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease Who Are Still Symptomatic After Optimal Medical Treatment
NCT07041359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DaZhu Rhodiola Rosea Capsule
DaZhu Rhodiola Rosea Capsule
Oral administration, 4 capsules, 3 times a day, for 8 weeks
DaZhu Rhodiola Rosea Simulation Capsule
DaZhu Rhodiola Rosea Simulation Capsule
Oral administration, 4 capsules, 3 times a day, for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DaZhu Rhodiola Rosea Capsule
Oral administration, 4 capsules, 3 times a day, for 8 weeks
DaZhu Rhodiola Rosea Simulation Capsule
Oral administration, 4 capsules, 3 times a day, for 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Coronary heart disease with grade Ⅱ or Ⅲ stable or unstable angina (≥ 2 times per week), or residual angina-like symptoms 1 month to 1 year post percutaneous coronary intervention (PCI) or 3 months to 1 year post coronary artery bypass surgery (CABG)
* Written informed consent
Exclusion Criteria
* Patients who plan to undergo revascularization in the next 3 months
* Congestive heart failure, acute myocarditis or pericarditis, thrombophlebitis, pulmonary embolism, or severe neurosis within 3 months prior to admission
* Patients with uncontrolled high blood pressure (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg), severe cardiopulmonary insufficiency (cardiac function grade Ⅲ, Ⅳ or left ventricular ejection fraction (LVEF) \< 40%), severe arrhythmia (rapid atrial fibrillation and flutter, paroxysmal ventricular tachycardia, degree Ⅱ type Ⅱ and degree Ⅲ atrioventricular block, etc.)
* Severe liver, kidney and hematopoietic system dysfunction or psychosis (serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2 times the normal upper limit, or serum creatinine \> 1.5 times the normal upper limit)
* History of bleeding or treatment with warfarin
* Implanted pacemakers
* Pregnant or lactating women
* Allergic to study drugs
* Legal disability (blindness, deafness, dumbness, intellectual disability, mental disability, physical disability)
* Patients who participated in other clinical trials within 3 months
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu Kangyuan Pharmaceutical Co. Ltd
UNKNOWN
Beijing Anzhen Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shao-Ping Nie
Professor of Medicine, Director, Emergency & Critical Care Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Anzhen Hospital, Capital Medical University
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.